BerGenBio planning Oslo IPO

BerGenBio A/S (Bergen, Norway) said it plans to launch an IPO underwritten by ABG Sundal Collier, Arctic Securities and DNB Markets on the Oslo exchange. The company said it will conduct a public offering to Norwegian and Swedish institutional and retail investors, as well as an international private placement.

The company raised NOK212 million ($25.1 million) in a March 2016 venture round. Its lead candidate BGB324 is in Phase II testing to treat non-small cell lung cancer (NSCLC) and acute myelogenous leukemia (AML). BerGenBio has exclusive, worldwide rights to the small molecule inhibitor of AXL receptor tyrosine kinase (AXL; UFO) from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) (see BioCentury Extra, March 18, 2016)...